Human Alphafetoprotein CLIA Kit


Human Alphafetoprotein CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human Alphafetoprotein in serum.

For in-vitro diagnostics purposes only.


The Human Alphafetoprotein CLIA Kit is designed, developed, and produced for the quantitative measurement of human AFP level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of AFP.
Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with streptavidin coated magnetic particles and biotinylated anti-AFP polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immuno complex in the form of “magnetic particles–biotin AFP antibody–AFP–acridinium ester AFP antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then, trigger solutions are added to the reaction vessel and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are proportional to the concentration of a AFP in the sample. The amount of analyte in the sample is determined.


Catalog no. SKT-026
Target Alphafetoprotein
Species Human
Method Sandwich CLIA
Tests Per Kit 100 tests
Detection Flash AE Chemiluminescence
Sensitivity / LLOD ≤0.5 IU /mL
Dynamic Range 0.5 IU/mL to 1000.0 IU/mL
Total Incubation Time
Sample Type Serum
Sample Volume 20 µL
Storage Temperature 2-8 °C

Selected Literature

​​​​​​​1. Aoyagi Y. Carbohydrate-based measurements of alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconjugate Journal 1995; 12: 194-1992.
2. Zaninotto M, Ujka F, Lachin M, et al. Lectin-affinity electrophoresis for the detection of AFP microheterogeneities in patients with hepatocellular carcinoma. Anticancer Res, 1996, 16: 305-30.
3. Applicability of alpha-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy orfollow-up. Clin Chem Lab Med. 2007 Jul;45(7):932-933

For in-vitro diagnostic use.